Who is the Pharmaceutical Reform Alliance? Read in browser

Thank you for reading, Test Researcher! basic Subscription UPGRADE

M T Wed Th F 7 October, 2026

Biopharma's balance of power is shifting, and in January, Endpoints journalists will press the people at the center of it on who's rising, who's falling and where the industry may land by the end of the decade. Join us at #JPM27 for exclusive conversations and interviews you won't get anywhere else. Save $200 on your all-access pass with Early Bird, or join us virtually for free.

presented by The Patent Clock Is Al­ready Run­ning. Why De­vel­op­ment Speed Is Al­so a Com­mer­cial Strat­e­gy

news CAR-T biotech Caribou weighs its options after struggling to find funding In DC, a secretive new thorn has appeared in the pharma industry's side AstraZeneca heralds new R&D facility in that ‘other’ Cambridge

Oct 08 11:00 am ET Site-central discordance in oncology trial imaging: New benchmarks and management strategies sponsored by Perceptive Imaging Oct 13 11:00 am ET Commercial excellence and AI - a ripple, wave or a tsunami sponsored by ZS Oct 15 1:00 pm ET Insights into Polycystic Kidney Disease: The Potential of Clinicogenomic Data sponsored by Natera Oct 20 11:00 am ET Intelligent oversight and orchestration: How mission control is redefining R&D decision-making sponsored by ZS Oct 21 11:00 am ET From prediction to decision: Digital twins and predictive modeling in clinical development sponsored by Flatiron Oct 22 11:00 am ET A new model for clinical research – Expanding community trial access sponsored by Parexel Oct 28 10:30 am ET The evolution of MRD: From molecular detection to clinical decisions sponsored by ABBOTT

The entire healthcare ecosystem is more Silicon Valley-ified than ever before. What tech has actually changed? Is biopharma behind? Find out, join us for Health Tech day.

in case you missed it 1. ArriVent's lung cancer drug fails key late-stage trial, stock tanks 2. News Briefing KymaThera, Rouge raise VC funding; Vaxcyte, Spyre do public offerings 3. Lycia seeks IPO for antibody degraders as TRexBio, Retension set terms 4. AbbVie, Genmab trot out first-line DLBCL win for Epkinly in challenge to Polivy 5. Forbion gets Lilly's backing in Dutch VC's largest-ever fundraising haul 6. WHO endorses lifestyle changes over GLP-1 drugs in child obesity fight